Fast and scalable purification of a therapeutic full-length antibody based on process crystallization

Biotechnology and Bioengineering

Volumn 110, Issue 9, 2013, Pages 2452-2461

  Smejkal, Benjamin ^a   Agrawal, Neeraj J ^b   Helk, Bernhard ^c   Schulz, Henk ^c   Giffard, Marion ^c   Mechelke, Matthias ^a   Ortner, Franziska ^a   Heckmeier, Philipp ^a   Trout, Bernhardt L ^b   Hekmat, Dariusch ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Massachusetts Institute of Technology   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alternative to chromatography; CHO cell culture harvest; Purification process; Scale up; Stirred process crystallization; Therapeutic monoclonal antibody

Indexed keywords

CHO CELL CULTURES; CRYSTALLIZATION PROCESS; HIGH SALT CONCENTRATION; MONOCLONAL ANTIBODY PURIFICATION; PROTEIN A CHROMATOGRAPHY; PURIFICATION PROCESS; SCALE-UP; THERAPEUTIC MONOCLONAL ANTIBODIES;

BIOACTIVITY; CELL CULTURE; CHROMATOGRAPHY; MOLECULAR MODELING; MONOCLONAL ANTIBODIES; PROTEINS; RECRYSTALLIZATION (METALLURGY);

PURIFICATION;

DNA; IMMUNOGLOBULIN G1 ANTIBODY; PROTEIN A; SODIUM CHLORIDE;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CHROMATOGRAPHY; CONTINUOUS STIRRED TANK REACTOR; CRYSTALLIZATION; DISSOLUTION; DNA CONTENT; DRUG PURIFICATION; DRUG PURITY; FEMALE; MOLECULAR MODEL; NONHUMAN;

ALTERNATIVE TO CHROMATOGRAPHY; CHO CELL CULTURE HARVEST; PURIFICATION PROCESS; SCALE-UP; STIRRED PROCESS CRYSTALLIZATION; THERAPEUTIC MONOCLONAL ANTIBODY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; CRYSTALLIZATION; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; MODELS, MOLECULAR; TEMPERATURE; TROMETHAMINE;

EID: 84880790791     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24908     Document Type: Article

References (45)

1. Agrawal NJ, Helk B, Trout BL. 2012. A computational tool to predict the protein-protein interaction hot-spot residues from the structure of the unbound protein. Manuscript submitted for publication.
2. Alderton G, Fevold HL. 1946. Direct crystallization of lysozyme from egg white and some crystalline salts of lysozyme. J Biol Chem 164:1-5.
3. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5:21-31.
4. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. 2001. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci USA 98:10037-10041.
5. Crisman RL, Randolph TW. 2010. Crystallization of recombinant human growth hormone at elevated pressures: Pressure effects on PEG-induced volume exclusion interactions. Biotechnol Bioeng 107:663-672.
6. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. 2007. PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35:W522-W525.
7. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, Blank GS. 2001. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 18:301-327.
8. Garcia-Ruiz JM. 2003. Nucleation of protein crystals. J Struct Biol 142:22-31.
9. Giffard M, Ferte N, Ragot F, El Hajji M, Castro B, Bonnete F. 2011. Urate oxidase purification by salting-in crystallization: Towards an alternative to chromatography. PLoS ONE 6:e19013.
10. Gottschalk U. 2008. Bioseparation in antibody manufacturing: The good, the bad and the ugly. Biotechnol Prog 24:496-503.
11. Granick S, Michaelis L. 1942. Ferritin and apoferritin. Science 95:439-440.
12. Harris LJ, Skaletsky E, McPherson A. 1995. Crystallization of intact monoclonal antibodies. Proteins 23:285-289.
13. Harris LJ, Larson SB, Hasel KW, McPherson A. 1997. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36:1581-1597.
14. Harrison RG, Todd P, Rudge SR, Petrides DP. 2003. Bioseparations science and engineering. New York: Oxford University Press. 406 p.
15. Hasegawa H, Wendling J, He F, Trilisky E, Stevenson R, Franey H, Kinderman F, Li G, Piedmonte DM, Osslund T, Shen M, Ketchem RR. 2011. In vivo crystallization of human IgG in the endoplasmic reticulum of engineered Chinese hamster ovary (CHO) cells. J Biol Chem 286:19917-19931.
16. Haynes SR, Jelinek WR. 1981. Low molecular weight RNAs transcribed in vitro by RNA polymerase III from Alu-type dispersed repeats in Chinese hamster DNA are also found in vivo. Proc Natl Acad Sci USA 78:6130-6134.
17. Hekmat D, Hebel D, Schmid H, Weuster-Botz D. 2007. Crystallization of lysozyme: From vapor diffusion experiments to batch crystallization in agitated ml-scale vessels. Process Biochem 42:1649-1654.
18. Hopkins FG. 1900. On the separation of a pure albumin from egg-white. J Physiol 25:306-330.
19. Jacobsen C, Garside J, Hoare M. 1998. Nucleation and growth of microbial lipase crystals from clarified concentrated fermentation broths. Biotechnol Bioeng 57:666-675.
20. Jion AI, Goh L-T, Oh SKW. 2006. Crystallization of IgG1 by mapping its liquid-liquid phase separation curves. Biotechnol Bioeng 95:911-918.
21. Judge RA, Johns MR, White ET. 1995. Protein purification by bulk crystallization: The recovery of ovalbumin. Biotechnol Bioeng 48:316-323.
22. Judge RA, Forsythe EL, Pusey ML. 1998. The effect of protein impurities on lysozyme crystal growth. Biotechnol Bioeng 59:776-785.
23. Kenney AC, Chase HA. 1987. Automated production scale affinity purification of monoclonal antibodies. J Chem Technol Biotechnol 39:173-182.
24. Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS. 2001. Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A 907:145-154.
25. Kuczewski M, Fraud N, Faber R, Zarbis-Papastoitsis G. 2010. Development of a polishing step using a hydrophobic interaction membrane adsorber with a PER.C6-derived recombinant antibody. Biotechnol Bioeng 105:296-305.
26. Larson S, Day J, Greenwood A, Skaletsky E, McPherson A. 1991. Characterization of crystals of an intact monoclonal antibody for canine lymphoma. J Mol Biol 222:17-19.
27. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. 2012. Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101:102-115.
28. Lewus RA, Darcy PA, Lenhoff AM, Sandler SI. 2011. Interactions and phase behavior of a monoclonal antibody. Biotechnol Prog 27:280-289.
29. Liu HF, Ma J, Winter C, Bayer R. 2010. Recovery and purification process development for monoclonal antibody production. MAbs 2:480-499.
30. Low D, O'Leary R, Pujar NS. 2007. Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci 848:48-63.
31. MacKerell AD, Bashford D, Bellott Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. 1998. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616.
32. Margolin AL, Navia MA. 2001. Protein crystals as novel catalytic materials. Angew Chem Int Ed Engl 40:2204-2222.
33. Przybycien TM. 1998. Protein-protein interactions as a means of purification. Curr Opin Biotechnol 9:164-170.
34. Rey G, Wendeler MW. 2012. Full automation and validation of a flexible ELISA platform for host cell protein and protein A impurity detection in biopharmaceuticals. J Pharm Biomed Anal 70:580-586.
35. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. 2001. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 293:1155-1159.
36. Shenoy B, Wang Y, Shan W, Margolin AL. 2001. Stability of crystalline proteins. Biotechnol Bioeng 73:358-369.
37. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-Application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848:28-39.
38. Smejkal B, Helk B, Rondeau JM, Anton S, Wilke A, Scheyerer P, Fries J, Hekmat D, Weuster-Botz D. 2013. Protein crystallization in stirred systems-Scale-up via the maximum local energy dissipation. Biotechnol Bioeng. doi: 10.1002/bit.24845
39. Sumner JB. 1926. The isolation and crystallization of the enzyme urease: Preliminary paper. J Biol Chem 69:435-441.
40. Takakura T, Ito T, Yagi S, Notsu Y, Itakura T, Nakamura T, Inagaki K, Esaki N, Hoffman RM, Takimoto A. 2006. High-level expression and bulk crystallization of recombinant l-methionine gamma-lyase, an anticancer agent. Appl Microbiol Biotechnol 70:183-192.
41. Trilisky E, Gillespie R, Osslund TD, Vunnum S. 2011. Crystallization and liquid-liquid phase separation of monoclonal antibodies and Fc-fusion proteins: Screening results. Biotechnol Prog 27:1054-1067.
42. Weber M, Jones MJ, Ulrich J. 2008. Optimisation of isolation and purification of the jack bean enzyme urease by extraction and subsequent crystallization. Food Bioprod Process 86:43-52.
43. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393-1398.
44. Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. 2003. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci USA 100:6934-6939.
45. Zang Y, Kammerer B, Eisenkolb M, Lohr K, Kiefer H. 2011. Towards protein crystallization as a process step in downstream processing of therapeutic antibodies: Screening and optimization at microbatch scale. PLoS ONE 6:e25282.